Radius patents expiration
1. Binosto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7964212 | RADIUS | Effervescent compositions comprising phosphonates and methods related thereto |
Mar, 2023
(1 year, 1 month ago) | |
| US7488496 | RADIUS | Effervescent compositions comprising bisphosphonates and methods related thereto |
Aug, 2023
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9592195 | RADIUS | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
Dec, 2031
(7 years from now) | |
Drugs and Companies using ALENDRONATE SODIUM ingredient
Market Authorisation Date: 12 March, 2012
Treatment: NA
Dosage: TABLET, EFFERVESCENT;ORAL
More Information on Dosage
BINOSTO family patents
2. Tymlos patents expiration
TYMLOS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748382 | RADIUS | Method of drug delivery for bone anabolic protein |
Oct, 2027
(3 years from now) | |
| US8148333 | RADIUS | Stable composition comprising a PTHrP analogue |
Nov, 2027
(3 years from now) | |
| USRE49444 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(7 years from now) | |
| US7803770 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(7 years from now) | |
| US10996208 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(14 years from now) | |
| US11782041 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(14 years from now) | |
| US11680942 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog |
Jan, 2040
(15 years from now) | |
| US11255842 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog |
Jan, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-270) | Sep 20, 2024 |
| New Indication(I-907) | Dec 19, 2025 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Treatment to increase bone density in men with osteoporosis at high risk for fracture; Use for detecting neutraliz...
Dosage: SOLUTION;SUBCUTANEOUS
How can I launch a generic of TYMLOS before it's drug patent expiration?
More Information on Dosage
TYMLOS family patents